PLUS1
4.29
-0.07 (-1.61%)
-0.07 (-1.61%)
Upgrade to Real-Time
Afterhours (Closed)
Low
4.03
High
17.99
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galecto Inc | GLTO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.07 | -1.61% | 4.29 | 00:00:05 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.32 | 4.27 | 4.35 | 4.29 | 4.36 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 4.10 | 5.13 | 1.03 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 283 | 33,080 | $ 4.30 | $ 142,144 | - | 4.03 - 17.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:43:41 | 1 | $ 4.71 | USD |
Period:
Draw Mode:
Galecto Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 108.37M | 25.26M | 19.59M | $ - | $ - | -7.86 | -0.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 201.00k | 0.30% |
Galecto News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLTO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.48 | 4.55 | 4.1412 | 4.38 | 106,717 | -0.19 | -4.24% |
| 1 Month | 5.03 | 5.15 | 4.03 | 4.45 | 297,287 | -0.74 | -14.71% |
| 3 Months | 5.51 | 16.41 | 4.03 | 5.91 | 1,296,315 | -1.22 | -22.14% |
| 6 Months | 12.73 | 16.41 | 4.03 | 5.97 | 613,514 | -8.44 | -66.3% |
| 1 Year | 15.77 | 17.99 | 4.03 | 6.22 | 426,316 | -11.48 | -72.8% |
| 3 Years | 15.77 | 17.99 | 4.03 | 6.22 | 426,316 | -11.48 | -72.8% |
| 5 Years | 15.77 | 17.99 | 4.03 | 6.22 | 426,316 | -11.48 | -72.8% |
Galecto Description
| Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
